EU Approves Merck KGaA's Erbitux For A Subtype Of Cancer
The European Commission has approved the use of Merck KGaA (MRK.XE) drug Erbitux for treatment of a subtype of cancer, the German pharmaceutical company said Monday. MAIN FACTS: - The Commission has approved an update of the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer. - The approval follows the positive opinion from the Committee for Medicinal Products for Human Use.
Help employers find you! Check out all the jobs and post your resume.